Antimicrobial Resistance in Vulvovaginitis

Area of Science:

• Medical Mycology
• Antimicrobial Resistance
• Vaginal Infections

Background:

• Antimicrobial resistance significantly impacts clinical medicine, yet its role in vaginal infections is largely unexplored.
• Current evidence does not strongly link frequent relapses of bacterial vaginosis or vulvovaginal candidiasis to antimicrobial resistance.
• Metronidazole-resistant trichomoniasis is exceptionally rare.

Purpose of the Study:

• To investigate the current state of antimicrobial resistance in common vaginal infections.
• To explore the potential impact of antimicrobial agent misuse on resistance patterns in vaginal fungi.

Main Methods:

• Review of existing literature on antimicrobial resistance in bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.
• Analysis of the potential for resistance development due to over-the-counter and systemic azole use.

Main Results:

• Limited evidence suggests antimicrobial resistance is not a primary driver for relapses in bacterial vaginosis or vulvovaginal candidiasis.
• Metronidazole resistance in trichomoniasis remains uncommon.
• Potential for increased azole resistance in Candida albicans and intrinsic azole resistance in non-albicans species (e.g., Candida glabrata) due to widespread azole exposure.

Conclusions:

• Antimicrobial resistance is not a significant factor in common vaginal infections currently.
• Widespread use of azoles may promote the emergence of azole-resistant Candida species, particularly non-albicans strains like Candida glabrata.
• Further surveillance of resistance patterns in vaginal mycoses is warranted.